Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Controversial billionaire George Soros may no longer be actively managing his namesake fund, Soros Fund Management, but the fund's quarterly activity remains a focal point for investors. The Soros Fund Management, after all, has consistently beat the broader markets since its inception in 1969.
So, what has the fund been up to in recent quarters? Interestingly enough, one of the Soros Fund's largest moves in the third quarter of 2017 was to buy additional put options for struggling drugmakers Valeant Pharmaceuticals International (NYSE: VRX) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA).
Image source: Getty Images.
Source: Fool.com
Bausch Health Companies Inc. Aktie
5,18 €
-1,77 %
Deutliche Kaufsignale für Bausch Health Companies Inc. mit mehreren Buy- und keinen Sell-Einschätzungen.
Das Kursziel von 12 € für Bausch Health Companies Inc. impliziert eine potenzielle Verdopplung gegenüber dem aktuellen Kurs von 5.18 €.
